A recent study performed by Lead Researcher, Chester Douglass, of Harvard University, unveiled that, investigated bone fluoride levels in individuals with osteosarcoma, (which is a rare, primary malignant bone tumor that is more prevalent in males,) found no serious association between bone fluoride levels and the risk for osteosarcoma was detected in this case-control study.
Logistic regression of the incident cases of osteosarcoma (N=137) and tumor controls (N=51;) adjusting for age and sex, as well as potential confounders of osteosarcoma were used to estimate odds ratios (OR) and 95% confidence intervals (CI.) There was no significant difference in bone fluoride levels between cases and controls. The OR adjusted for age, gender, and a history of broken bones was 1.33 (95% CI: 0.56-3.15.)
